ATRA
NASDAQ · Biotechnology
Atara Biotherapeutics Inc
$8.09
-0.42 (-4.94%)
Open$8.51
Previous Close$8.51
Day High$8.51
Day Low$7.99
52W High$19.15
52W Low$3.92
Volume—
Avg Volume50.0K
Market Cap85.42M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
-13.0% upside
Current
$8.09
$8.09
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 100.27M | 80.96M | 4.60M |
| Net Income | 27.14M | 19.72M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 31.53M | 24.19M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |